EUCTR2007-005534-36-GB进行中(未招募)不适用
The effect of Exenatide on satiety, metabolic parameters and regional brain activation in response to nutrient ingestion in Type 2 diabetes.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •People with Type 2 diabetes:
- •1. 18-65 years of age
- •2. Type 2 diabetes, with evidence of residual insulin secretion and insulin resistance as determined by absence of requirement for insulin therapy
- •3. HbA1c (gold standard blood glucose control measure) 5.5-9.0%
- •4. Diabetes controlled by either diet and exercise +/- combination of oral hypoglycaemic therapy (Metformin, Sulphonylurea, Meteglinides and/or thiazolidinediones.
- •5. Diabetes therapy unchanged for three months prior to the study
- •6. Clear understanding of written and spoken English
- •7. Ability to given written consent
- •Healthy volunteers (subjects without diabetes for generation of normative data with this scanning protocol):18-65 years of age with no significant medical history and not taking regular medications, who have a clear understanding of written and spoken English and are able to given written consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Uncontrolled hypertension (blood pressure)
- •2. Unstable diabetes control as judged by the investigator
- •3. Insulin treated diabetes
- •4. Cardiac failure (NYHA Grade 2 or higher - objective measure of heart failure)
- •5. Inabililty fully to comprehend verbal and written English/understand the protocol
- •6. Left handed subjects
- •7. Weight >120kg.
- •8. Contraindictation to fMRI scanning (metal implants; shrapnel injuries; cardiac pacemaker; claustrophobia)
- •9. Subjects who suffer from claustrophobia
- •10. Needle phobic subjects
- •11. Patients taking recreational drugs
- •12. Patients who have received any investigational drugs in the past 3 months.
- •13. Pregnant females or those actively trying to become pregnant
- •14. Subjects at high risk or with blood bourne infectious disease, such as HIV, Hepatitis B/C.
研究者
相似试验
已完成
4 期
Effect of Exenatide in Obese Patients With Accelerated Gastric EmptyingObesityNCT02160990Mayo Clinic20
进行中(未招募)
不适用
Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome - Effects of exenatide on appetite and ghrelin in Prader-Willi SyndromeEUCTR2010-023179-25-GBAintree University Hospital NHS Foundation Trust
已完成
4 期
The Effect of Exenatide on Weight and Hunger in Obese, Healthy WomenImpaired Glucose ToleranceObesityNCT00456885Beth Israel Deaconess Medical Center41
已完成
4 期
Bioenergetic Alterations After Exenatide AdministrationHealthyNCT00623545University of Wisconsin, Madison28
已完成
3 期
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00135330AstraZeneca137
